论文部分内容阅读
目的探讨区域性缓释化疗对于进展期胃癌患者进行根治术的安全性评价。方法选取2008年1月至12月在我院进行治疗的进展期胃癌患者66例,在手术关腹前进行腹腔低渗温热灌注,且使用5-Fu缓释剂植入进行区域性缓释化疗,另取66例进展期胃癌患者进行低渗温热灌注治疗。结果观察组患者引流管流量、引流管留置时间与对照组相比明显较高(P<0.05),两组患者术后体温恢复时间、术后疼痛持续时间、术后5 d白细胞计数与吻合口漏、腹腔感染、切口感染等并发症发生率情况差异无统计学意义(P>0.05)。结论 5-Fu区域缓释化疗在胃癌根治术后仅提高了引流管流量、留置时间,在其他临床表征上无显著表现,区域缓释化疗能够有效降低化疗毒性,值得推广。
Objective To evaluate the safety of regional slow-release chemotherapy in patients with advanced gastric cancer. Methods Sixty-six patients with advanced gastric cancer who were treated in our hospital from January 2008 to December 2008 were treated with intraperitoneal hypothermic warm perfusion before surgery and 5-Fu sustained-release agent Chemotherapy, another 66 cases of advanced gastric cancer patients undergoing hypotonic warm perfusion therapy. Results The drainage volume of the drainage tube and the retention time of the drainage tube in the observation group were significantly higher than those in the control group (P <0.05). The postoperative recovery time of body temperature, the duration of postoperative pain, the white blood cell count at 5 days after operation and the anastomosis There were no significant differences in the incidence of complications such as leakage, abdominal infection and incision infection (P> 0.05). Conclusion The 5-Fu regional slow-release chemotherapy only increases the drainage and retention time of the drainage tube after radical gastrectomy, and has no significant clinical manifestations. The regional slow-release chemotherapy can effectively reduce the toxicity of chemotherapy and is worth promoting.